Table 1 Comparison of patient characteristics between patients with and without major bleeding

Baseline characteristics

 Age (years)

52.7 ± 17.9

61.7 ± 14.6

52.5 ± 17.9

<0.001

 Men

1877 (65.1%)

42 (73.7%)

1835 (65.0%)

0.17

 Body weight (kg)

68.8 ± 18.4

70.1 ± 14.4

68.8 ± 18.5

0.62

 Height (cm)

164.3 ± 12.4

164.1 ± 8.7

164.3 ± 12.4

0.88

 Body mass index (kg/m²)

25.3 ± 5.4

25.9 ± 4.6

25.2 ± 5.4

0.39

  Body mass index > 30 kg/m²

456 (15.8%)

11 (19.3%)

445 (15.8%)

0.47

 D-dimer level at admission (μg/mL)

0.8 (0.5–1.3)

1.6 (0.9–4.3)

0.8 (0.5–1.3)

0.05

Comorbidities

 Hypertension

869 (30.2%)

33 (57.9%)

836 (29.6%)

<0.001

 Diabetes mellitus

595 (20.6%)

21 (36.8%)

574 (20.3%)

0.002

 Heart disease

254 (8.8%)

12 (21.1%)

242 (8.6%)

0.001

 Respiratory disease

298 (10.3%)

9 (15.8%)

289 (10.2%)

0.17

 Active cancer

60 (2.1%)

2 (3.5%)

58 (2.1%)

0.45

 History of major bleeding

26 (0.9%)

5 (8.8%)

21 (0.7%)

<0.001

 History of VTE

15 (0.5%)

0 (0%)

15 (0.5%)

0.58

Severity of COVID-19 at admission

 Mild

1732 (60.1%)

8 (14.0%)

1724 (61.0%)

<0.001

 Moderate (Need oxygen)

922 (32.0%)

21 (36.8%)

901 (31.9%)

 Severe (Need mechanical ventilation or ECMO)

228 (7.9%)

28 (49.1%)

200 (7.1%)

Worst severity of COVID-19 during hospitalization

 Mild

1278 (44.3%)

4 (7.0%)

1274 (45.1%)

<0.001

 Moderate (Need oxygen)

1225 (42.5%)

14 (24.6%)

1211 (42.9%)

 Severe (Need mechanical ventilation or ECMO)

379 (13.2%)

39 (68.4%)

340 (12.0%)

Pharmacological thromboprophylaxis regimens

 Non-anticoagulants

1649 (57.2%)

6 (10.5%)

1643 (58.2%)

<0.001

 Anticoagulants

1233 (42.8%)

51 (89.5%)

1182 (41.8%)

  Prophylactic dose (LMWH or UFH)

889/1233 (72.1%)

20/51 (39.2%)

869/1182 (73.5%)

-

  Therapeutic dose (UFH)

161/1233 (13.1%)

26/51 (51.0%)

135/1182 (11.4%)

-

  Therapeutic dose (Warfarin or DOAC)

183/1233 (14.8%)

5/51 (9.8%)

178/1182 (15.1%)

-